FindTrial
Sign In

Benefit of Vitamin D supplementation in treatment of Polycystic ovary syndrome (PCOS)

Role of vitamin D supplementation in treatment of Polycystic ovary syndrome (PCOS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/02/012104
Enrollment
336
Registered
2018-02-23
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- POLYCYSTIC OVARY SYNDROME

Interventions

Intervention1: Metformin,Spironolactone or Pioglitazone: Metformin, Spironolactone or Pioglitazone with ot without Cholecalciferol

Sponsors

Intramural
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All women who have oligomenorrhea, hyperandrogensim (hirsuitism, acne or androgenic alopecia) or USG suggestion of polcystic ovary morphology

Exclusion criteria

Exclusion criteria: NCAH, Thyroid dysfunction,Systemic disorders and drug intake

Design outcomes

Primary

MeasureTime frame
Effect on clinical, biochemical and hormonal parametersTimepoint: 0, 3 and 6 months—

Secondary

MeasureTime frame
To study the prevalence of vitamin D deficiency in women with PCOS. 2) To correlate vitamin D levels with various clinical, biochemical and insulin sensitivity parameters of PCOS. Timepoint: 0,12,24 WEEKS—

Countries

India

Contacts

Public ContactDr Mohd Ashraf Ganie

All India Institute of Medical Sciences (AIIMS)

ashraf.endo@gmail.com01126593968

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026